Postherpetic Neuralgia | Treatment Algorithms: Claims Data Analysis | US | 2024
Postherpetic neuralgia (PHN) is characterized by itching, numbness, and burning, as well as stabbing, shooting, or shock-like pain. PHN is managed with multiple established, generic antiepileptic drugs (e.g., gabapentin, pregabalin), antidepressants (e.g., amitriptyline, duloxetine), and dual-acting opioid analgesics (e.g., tramadol), as well as topical lidocaine (e.g., Scilex’s ZTlido) and topical capsaicin (e.g., Averitas’s Qutenza), However, current analgesics fall short in providing adequate relief due to side effects, prolonged titration, inadequate dosing, poor compliance, and low treatment satisfaction. Thus, unmet need and opportunity exist for new options, particularly those with novel mechanisms of action. The successful launch of a novel analgesic for PHN or other forms of neuropathic pain will require a granular understanding of treatment patterns in PHN, a common gateway market for emerging neuropathic pain drugs.
Questions answered
- What patient shares do key treatments garner by line of therapy in newly diagnosed PHN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed patients?
- How have branded agents offering incremental safety, tolerability, or dosing benefits fared in this highly generic market? How have they been integrated into the treatment algorithm, and what is their source of business?
- What percentage of PHN patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of PHN patients are treated with monotherapy vs. combination therapy? What are the most used combinations?
- What are the drug-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key feature
Dashboards featuring interactive visuals, easy navigation, and expanded analyses
Geography: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Collegium Pharmaceuticals, BioDelivery Sciences International, Averitas, Scilex, Kowa Pharmaceuticals, Azurity Pharmaceuticals, Almatica
Key drugs: Gabapentin, pregabalin, Qutenza, ZTlido, Gralise, Horizant, amitriptyline, duloxetine, venlafaxine, milnacipran, topiramate, NSAIDs, opioids, tramadol, tapentadol
Key analysis provided
- Brand / therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flowcharts
